Univariate Cox model for PFS
| Variable . | n (%) N = 240 . | PFS, 2 y . | |
|---|---|---|---|
| HR (95% CI) . | P value . | ||
| Sex | |||
| Female | 108 (45) | 0.8 (0.6-1.1) | |
| Male | 132 (55) | 1.0 | .3 |
| Diagnosis | |||
| MDS | 114 (47) | 0.9 (0.7-1.2) | |
| AML | 126 (52) | 1.0 | .4 |
| Therapy-related AML | |||
| Yes | 40 (32) | 1.4 (0.9-2.1) | |
| No | 86 (68) | 1.0 | .1 |
| Cytogenetics | |||
| Complex | 171 (71) | 1.0 | |
| 5q/7q | 18 (7) | 0.7 (0.4-1.2) | .2 |
| Other | 44 (18) | 0.3 (0.2-0.6) | <.001 |
| Missing | 7 (3) | 1.03 (0.4-2.5) | .9 |
| Hit status | |||
| Monohit | 66 (27) | 1.0 | |
| Multihit | 166 (69) | 2.1 (1.4-3.1) | <.001 |
| Missing | 8 (3) | 0.9 (0.3-2.5) | .8 |
| VAF, max | |||
| <10 | 57 (25) | 1.0 | .006 |
| 10-49 | 118 (53) | 1.8 (1.2-2.7) | <.001 |
| ≥50 | 49 (22) | 3.6 (2.2-5.7) | |
| Missing | 16 | ||
| EA score | |||
| ≥52 | 212 (88) | 1.1 (0.6-1.9) | .8 |
| <52 | 19 (8) | 1.0 | |
| Missing | 9 (4) | excluded | |
| TP53 detected pre-TP | |||
| Yes | 46 (49) | 1.05 (0.5-2.1) | .9 |
| No | 22 (23) | 1.0 | |
| N/A | 26 (28) | 1.3 (0.7-2.5) | .3 |
| Number of TP53 mutations | |||
| 1 | 169 (70) | 1.0 | |
| 2 | 57 (24) | 1.01 (0.7-1.4) | .9 |
| >2 | 14 (6) | 1.2 (0.6-2.2) | .6 |
| Truncated TP53 mutation | |||
| Absent | 201 (84) | 1.0 | |
| Present | 39 (16) | 1.4 (0.9-1.9) | .1 |
| Disease status at dx | |||
| CR1 or 2 vs all other | 0.7 (0.5-0.9) | .04 | |
| Prior disease directed treatment | |||
| 1 vs >1 line of treatment | 1.3 (0.96-1.8) | .09 | |
| Dx status/MRD | |||
| CR1 or CR2/MRD negative | 52 (22) | 1.0 | |
| CR1 or CR2/MRD positive | 28 (12) | 1.8 (1.1-3.2) | .03 |
| CR1 or CR2/MRD missing | 13 (5) | 1.4 (0.7-2.9) | .3 |
| All other | 147 (61) | 1.7 (1.2-2.6) | .006 |
| Age at TP, median | |||
| >60 | 62 (18-75) [56, 67] | 0.8 (0.6-1.02) | .07 |
| HCT-CI | 4 (0-10) [2, 5] | ||
| 0-1 | 49 (20) | 1.0 | |
| 2 | 24 (10) | 1.01 (0.6-1.8) | .9 |
| 3 | 39 (16) | 1.5 (0.9-2.5) | .09 |
| 4 | 42 (17) | 0.9 (0.5-1.5) | .7 |
| >4 | 86 (36) | 1.2 (0.8-1.9) | .3 |
| Donor type | |||
| MSD | 61 (25) | 1.0 | |
| MUD | 126 (52) | 1.4 (0.9-2.1) | .055 |
| Haplo | 42 (17) | 1.5 (0.9-2.4) | .07 |
| Ag MM | 11 (5) | 1.1 (0.5-2.5) | .8 |
| MRD vs all other | 0.7 (0.5-0.9) | .04 | |
| Conditioning intensity | |||
| Reduced intensity | 99 (41) | ||
| Melphalan | 86 | 1.0 | |
| Busulfan/Other | 11/2 | 1.5 (0.8-2.6) | .2 |
| Myeloablative | 141 (59) | 0.9 (0.7-1.3) | .7 |
| Busulfan | 141 | ||
| Donor/recipient CMV | |||
| R/R | 100 (42) | 0.9 (0.5-1.4) | .6 |
| R/NR | 23 (10) | 0.6 (0.3-1.3) | .2 |
| NR/R | 88 (37) | 0.9 (0.6-1.6) | .9 |
| NR/NR | 29 (12) | ||
| Recipient R | 1.1 (0.8-1.6) | .5 | |
| Stem cell source | 166 (69) | .3 | |
| PB | 74 (31) | 1.0 | |
| BM | 60 (98) | ||
| MSD: | |||
| PB | .9 | ||
| MUD: | |||
| PB | 86 (68) | 0.9 (0.6-1.5) | .5 |
| BM | 40 (32) | 1.0 | |
| Haplo: | |||
| PB | 13 (31) | 0.8 (0.4-1.6) | .7 |
| BM | 29 (69) | 1.0 | |
| Ag MM: | |||
| PB | 7 (64) | 0.8 (0.2-3.4) | .4 |
| BM | 4 (36) | 1.0 | |
| Haplo/Ag MM PB vs BM | 0.8 (0.4-1.4) | ||
| Variable . | n (%) N = 240 . | PFS, 2 y . | |
|---|---|---|---|
| HR (95% CI) . | P value . | ||
| Sex | |||
| Female | 108 (45) | 0.8 (0.6-1.1) | |
| Male | 132 (55) | 1.0 | .3 |
| Diagnosis | |||
| MDS | 114 (47) | 0.9 (0.7-1.2) | |
| AML | 126 (52) | 1.0 | .4 |
| Therapy-related AML | |||
| Yes | 40 (32) | 1.4 (0.9-2.1) | |
| No | 86 (68) | 1.0 | .1 |
| Cytogenetics | |||
| Complex | 171 (71) | 1.0 | |
| 5q/7q | 18 (7) | 0.7 (0.4-1.2) | .2 |
| Other | 44 (18) | 0.3 (0.2-0.6) | <.001 |
| Missing | 7 (3) | 1.03 (0.4-2.5) | .9 |
| Hit status | |||
| Monohit | 66 (27) | 1.0 | |
| Multihit | 166 (69) | 2.1 (1.4-3.1) | <.001 |
| Missing | 8 (3) | 0.9 (0.3-2.5) | .8 |
| VAF, max | |||
| <10 | 57 (25) | 1.0 | .006 |
| 10-49 | 118 (53) | 1.8 (1.2-2.7) | <.001 |
| ≥50 | 49 (22) | 3.6 (2.2-5.7) | |
| Missing | 16 | ||
| EA score | |||
| ≥52 | 212 (88) | 1.1 (0.6-1.9) | .8 |
| <52 | 19 (8) | 1.0 | |
| Missing | 9 (4) | excluded | |
| TP53 detected pre-TP | |||
| Yes | 46 (49) | 1.05 (0.5-2.1) | .9 |
| No | 22 (23) | 1.0 | |
| N/A | 26 (28) | 1.3 (0.7-2.5) | .3 |
| Number of TP53 mutations | |||
| 1 | 169 (70) | 1.0 | |
| 2 | 57 (24) | 1.01 (0.7-1.4) | .9 |
| >2 | 14 (6) | 1.2 (0.6-2.2) | .6 |
| Truncated TP53 mutation | |||
| Absent | 201 (84) | 1.0 | |
| Present | 39 (16) | 1.4 (0.9-1.9) | .1 |
| Disease status at dx | |||
| CR1 or 2 vs all other | 0.7 (0.5-0.9) | .04 | |
| Prior disease directed treatment | |||
| 1 vs >1 line of treatment | 1.3 (0.96-1.8) | .09 | |
| Dx status/MRD | |||
| CR1 or CR2/MRD negative | 52 (22) | 1.0 | |
| CR1 or CR2/MRD positive | 28 (12) | 1.8 (1.1-3.2) | .03 |
| CR1 or CR2/MRD missing | 13 (5) | 1.4 (0.7-2.9) | .3 |
| All other | 147 (61) | 1.7 (1.2-2.6) | .006 |
| Age at TP, median | |||
| >60 | 62 (18-75) [56, 67] | 0.8 (0.6-1.02) | .07 |
| HCT-CI | 4 (0-10) [2, 5] | ||
| 0-1 | 49 (20) | 1.0 | |
| 2 | 24 (10) | 1.01 (0.6-1.8) | .9 |
| 3 | 39 (16) | 1.5 (0.9-2.5) | .09 |
| 4 | 42 (17) | 0.9 (0.5-1.5) | .7 |
| >4 | 86 (36) | 1.2 (0.8-1.9) | .3 |
| Donor type | |||
| MSD | 61 (25) | 1.0 | |
| MUD | 126 (52) | 1.4 (0.9-2.1) | .055 |
| Haplo | 42 (17) | 1.5 (0.9-2.4) | .07 |
| Ag MM | 11 (5) | 1.1 (0.5-2.5) | .8 |
| MRD vs all other | 0.7 (0.5-0.9) | .04 | |
| Conditioning intensity | |||
| Reduced intensity | 99 (41) | ||
| Melphalan | 86 | 1.0 | |
| Busulfan/Other | 11/2 | 1.5 (0.8-2.6) | .2 |
| Myeloablative | 141 (59) | 0.9 (0.7-1.3) | .7 |
| Busulfan | 141 | ||
| Donor/recipient CMV | |||
| R/R | 100 (42) | 0.9 (0.5-1.4) | .6 |
| R/NR | 23 (10) | 0.6 (0.3-1.3) | .2 |
| NR/R | 88 (37) | 0.9 (0.6-1.6) | .9 |
| NR/NR | 29 (12) | ||
| Recipient R | 1.1 (0.8-1.6) | .5 | |
| Stem cell source | 166 (69) | .3 | |
| PB | 74 (31) | 1.0 | |
| BM | 60 (98) | ||
| MSD: | |||
| PB | .9 | ||
| MUD: | |||
| PB | 86 (68) | 0.9 (0.6-1.5) | .5 |
| BM | 40 (32) | 1.0 | |
| Haplo: | |||
| PB | 13 (31) | 0.8 (0.4-1.6) | .7 |
| BM | 29 (69) | 1.0 | |
| Ag MM: | |||
| PB | 7 (64) | 0.8 (0.2-3.4) | .4 |
| BM | 4 (36) | 1.0 | |
| Haplo/Ag MM PB vs BM | 0.8 (0.4-1.4) | ||
Ag MM, antigen mismatch; BM, bone marrow; Haplo, haploidentical; MRD, matched related donor; MUD, matched unrelated donor; PB, peripheral blood; R, reactive; TP, transplant.